Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carl Basamania

Orthopaedic Surgery Seattle, WA Medical Doctor

NPI 1295822930 CMS profile 286212

601 Broadway, 6Th Floor, Seattle, WA 98122

Open in the dashboard

General payments

$355,819

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carl Basamania of Seattle, WA is reported in the CMS Open Payments database as having received $355,819 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,178 9
2024 General $39,251 9
2023 General $34,914 11
2022 General $65,032 35
2021 General $35,477 21
2020 General $86,450 38
2019 General $54,518 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carl Basamania
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Carl Basamania were reported at $40,178. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Carl Basamania Orthopaedic Surgery median Middle half National median
2019 $54,518 $644 $140–$2,844 $163
2020 $86,450 $312 $75–$1,860 $114
2021 $35,477 $520 $117–$2,495 $132
2022 $65,032 $598 $128–$2,731 $149
2023 $34,914 $461 $128–$2,264 $160
2024 $39,251 $497 $134–$2,475 $164
2025 $40,178 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $141,590 71 payments
  2. Zimmer Biomet Holdings, Inc. $141,339 47 payments
  3. DePuy Synthes Products, Inc. $69,767 60 payments
  4. Arthrex, Inc. $1,327 3 payments
  5. Summit Surgical Corp. $1,200 1 payment
  6. DePuy Synthes Sales Inc. $458 9 payments
  7. Pacira Pharmaceuticals Incorporated $87 1 payment
  8. Stryker Corporation $51 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $179,045 41 payments
  2. Royalty or License $153,674 43 payments
  3. Travel and Lodging $17,877 51 payments
  4. Food and Beverage $2,724 56 payments
  5. Education $2,499 2 payments
Products named General payments · program years 2019–2025
  1. A.L.P.S. $124,083 17 payments
  2. DELTA $63,748 34 payments
  3. GRYPHON $47,425 17 payments
  4. HEALIX $45,820 10 payments
  5. GLOBAL Ortho-Shoulder $40,807 20 payments
  6. HEALIX KNOTLESS PEEK $40,132 14 payments
  7. Gryphon Orthocord $40,030 10 payments
  8. BIOLOX DELTA $37,142 17 payments
  9. GLOBAL Ortho-Shoulder $27,517 15 payments
  10. Alps Plates and Instruments $11,947 10 payments
  11. Other $14,019 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

261

Median for Orthopedic Surgery: 203

Drug cost

$6,142

Median for Orthopedic Surgery: $1,433

Branded share of claims

5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 229 $6,016
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $93
Amoxicillin Generic 19 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$176,810

Of which drugs: $1,433

Medicare patients

293

Average age 75

Services billed

5,091

171 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Ischemic heart disease 25%
Depression 18%
Diabetes 16%
Osteoporosis 16%
Chronic kidney disease 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 1,622 $164
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 18 2,371 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record